CTKBHealthcare · Medical DevicesThe 3 Wall Street analysts covering Cytek Biosciences, Inc. hold a median 12-month price target of $6 — -2.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 31 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Cytek Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (91): Reported profit is backed by cash, and the company is not expanding recklessly.
Growth (39): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CTKB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −2.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 May 2026 | Stephens & Co. | Maintains | Overweight | $5.50 → $4.75 |
| 12 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $6.00 → $5.50 |
| 8 Jan 2026 | TD Cowen | Maintains | Buy | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Overweight | — |
| 28 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 May 2025 | Goldman Sachs | Maintains | Sell | — |
| 19 Mar 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 4 Mar 2025 | Piper Sandler | Maintains | Overweight | — |
| 11 Nov 2024 | Piper Sandler | Maintains | Overweight | — |
| 13 Aug 2024 | Piper Sandler | Maintains | Overweight | — |
| 13 May 2024 | Piper Sandler | Maintains | Overweight | — |
| 6 Mar 2024 | Piper Sandler | Maintains | Overweight | — |
| 29 Feb 2024 | Goldman Sachs | Maintains | Buy | — |
| 14 Dec 2023 | Stephens & Co. | Initiates | Overweight | — |
| 9 Nov 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 24 Oct 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 16 Oct 2023 | Piper Sandler | Maintains | Overweight | — |
| 19 July 2023 | Raymond James | Initiates | Market Perform | — |
| 11 May 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 May 2023 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CTKB appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Cytek Biosciences, Inc. returned +60.2% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 2% of US stocks
Cheaper than 30% of US stocks
Cheaper than 36% of US stocks
Cheaper than 88% of US stocks
Higher than 42% of US stocks
Higher than 43% of US stocks
Higher than 72% of US stocks
Higher than 19% of US stocks
Higher than 12% of US stocks
Higher than 30% of US stocks
Higher than 30% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cytek Biosciences, Inc. has a market value of $795.5M and an enterprise value of $583.4M.
Revenue in the twelve months to 30 June 2026: $206.7M. The latest quarter grew 5.6% year on year.
Net income over the same four quarters: −$80.6M, a −39.0% net margin.
Diluted earnings per share, trailing twelve months: $−0.62.
Free cash flow in the twelve months to 30 June 2026: −$12.2M.
Cytek Biosciences, Inc. spent $63K on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 374.5×; forward P/E: 87.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Cytek Biosciences, Inc. employs 682 people — $303K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cytek Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Cytek Biosciences announced it will participate in upcoming investor conferences. The excerpt does not provide conference names or dates.
Why it matters — The announcement signals planned investor outreach, though the excerpt gives no further details about the events.
Zacks Investment Research says Cytek Biosciences lacks the two key ingredients associated with a likely earnings beat in its upcoming report. The headline frames analysts’ estimate as a decline in earnings.
Why it matters — CTKB watchers may note the article’s focus on expectations for the company’s upcoming earnings report.
Cytek Biosciences announced it will report its third-quarter 2026 financial results after market close on November 4, 2026. Management will host a conference call that day at 1:30 p.m. Pacific Time to discuss results, business developments, and outlook.
Why it matters — CTKB watchers can note the scheduled date and time for the company’s quarterly results and management discussion.
Cytek Biosciences expanded its Cytek Cloud digital ecosystem with a new Cloud Analysis tool, creating what the company describes as the industry's first end-to-end flow cytometry platform. The announcement extends the company's cloud-based digital capabilities.
Why it matters — The new Cloud Analysis tool strengthens Cytek's digital ecosystem and positions its flow cytometry platform as more integrated and end-to-end, which could appeal to existing and potential customers.
Zacks Investment Research reports that recent movements in the options market for Cytek Biosciences (CTKB) stock may indicate analysts and investors are anticipating a potential price spike. The article advises investors to pay close attention to the stock based on these options-market signals.
Why it matters — A CTKB watcher would care because unusual options-market activity can signal shifts in investor sentiment and expectations about the stock's upcoming direction.
The 3 Wall Street analysts covering Cytek Biosciences, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $7.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Cytek Biosciences, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytek Biosciences, Inc. 80 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Cytek Biosciences, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (91 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies -2.0% from the last close, and Ticker Nerd's factor model ranks Cytek Biosciences, Inc. 80 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Cytek Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTKB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $7.5 over the next 12 months.
Cytek Biosciences, Inc. returned +60.2% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Cytek Biosciences to Participate in Upcoming Investor Conferences". Cytek Biosciences announced it will participate in upcoming investor conferences. The excerpt does not provide conference names or dates.
Cytek Biosciences, Inc. is a cell analysis solutions company that develops and markets advanced flow cytometry systems, reagents, software, and services for biomedical research and clinical applications. The company’s portfolio centers on its Full Spectrum Profiling technology, which supports high-resolution, high-content, and high-sensitivity analysis of single cells. Its current product lineup includes the Aurora and Northern Lights cell analyzers, the Aurora CS cell sorter, and related integrated tools designed to help researchers study complex biological samples. Cytek Biosciences also offers conventional flow and image-based flow cytometry products through its acquired Amnis and Guava businesses, expanding its reach across cell analysis workflows. The company serves life science researchers and clinical laboratories with solutions used in areas such as immunology, cancer research, infectious disease, and inflammatory disease studies. Headquartered in Fremont, California, Cytek Biosciences focuses on providing a comprehensive platform for cell analysis in global research and applied science markets.
CEO Dr. Wenbin Jiang Ph.D. · 682 employees · United States · https://cytekbio.com
